Insmed
insmed.com
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?
Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision date. The application seeks full approval and broader
Read more
Report
Mizuho Securities Sticks to Its Buy Rating for Insmed (INSM)
Detailed price information for Insmed Inc (INSM-Q) from The Globe and Mail including charting and trades.
Read more
Report
Insmed Says FDA Grants Priority Review to Arikayce Supplemental Filing for MAC Lung Disease
Read more
Report
Insmed Incorporated Receives Fda Priority Review for Supplemental New Drug Application for Arikayce Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Avium ...
Read more
Report
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
Parnassus Investments, an investment management company, released the
Read more
Report
Report
Insmed Expands Community Impact During Fifth Annual Global Day of Good - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - Company Announcement - FT...
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Insmed's (INSM) New Drug Launch Is Reshaping The Whole Business
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year
Read more
Report
Show more news